Literature DB >> 11196169

The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system.

S T Eichhorst1, S Müerköster, M A Weigand, P H Krammer.   

Abstract

The CD95/CD95 ligand (CD95L) system has been shown to mediate chemotherapeutic drug-induced apoptosis in vitro. However, the contribution of the CD95 pathway to drug-induced apoptosis is controversial. We have shown previously that 5-fluorouracil (5-FU) induces apoptosis in vitro via the activation of the CD95/CD95L system. To study the effects of the chemotherapeutic drug 5-FU and the contribution of the CD95 system to 5-FU-induced apoptosis in vivo, we gave mice an i.p. injection of 5-FU. Apoptotic cell death peaked in thymocytes at 18 h after administration of 5-FU. Total organ weight and cell number in the thymus were reduced by approximately 40%. This cell loss was due to apoptosis, as measured in cell suspensions by measuring hypodiploid DNA content and by terminal deoxynucleotidyl transferase-mediated nick end labeling staining of tissue sections. The number of apoptotic cells correlated with the extent of weight loss and cell attrition of the organs. Furthermore, in the thymi of 5-FU-treated animals, CD95L was strongly up-regulated. Apoptosis of thymocytes was blocked in vivo with neutralizing anti-CD95L antibodies. In addition, cell loss in the thymus was negligible in lpr mice in comparison with wild-type mice. Thus, a significant portion of apoptosis of thymocytes in vivo on treatment with 5-FU is mediated via the CD95/CD95L pathway. Our findings therefore contribute to the understanding how chemotherapeutic drugs exert their effects in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11196169

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  Clinical application of ceramide in cancer treatment.

Authors:  Kazuki Moro; Masayuki Nagahashi; Emmanuel Gabriel; Kazuaki Takabe; Toshifumi Wakai
Journal:  Breast Cancer       Date:  2019-04-08       Impact factor: 4.239

Review 2.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

3.  Prognostic value of serum soluble Fas in patients with locally advanced unresectable rectal cancer receiving concurrent chemoradiotherapy.

Authors:  Qi-lian Liang; Zhou-yu Li; Guo-qiang Chen; Zhen-nan Lai; Bi-rong Wang; Jie Huang
Journal:  J Zhejiang Univ Sci B       Date:  2010-12       Impact factor: 3.066

Review 4.  Shared pathways: death receptors and cytotoxic drugs in cancer therapy.

Authors:  I Peták; J A Houghton
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

5.  Expression of Bcl-2 family member Bid in normal and malignant tissues.

Authors:  Maryla Krajewska; Juan M Zapata; Ivo Meinhold-Heerlein; Hirad Hedayat; Anne Monks; Herta Bettendorf; Ahmed Shabaik; Lukas Bubendorf; Olli-P Kallioniemi; Hoguen Kim; Guido Reifenberger; John C Reed; Stanislaw Krajewski
Journal:  Neoplasia       Date:  2002 Mar-Apr       Impact factor: 5.715

6.  FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.

Authors:  L Sehgal; R Mathur; F K Braun; J F Wise; Z Berkova; S Neelapu; L W Kwak; F Samaniego
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

7.  Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients.

Authors:  Yong Huang; Haijun Yu; Han Lei; Conghua Xie; Yahua Zhong
Journal:  Med Oncol       Date:  2014-01-28       Impact factor: 3.064

8.  CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells.

Authors:  Bryan C Barnhart; Patrick Legembre; Eric Pietras; Concetta Bubici; Guido Franzoso; Marcus E Peter
Journal:  EMBO J       Date:  2004-07-22       Impact factor: 11.598

9.  Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex.

Authors:  Jillian F Wise; Zuzana Berkova; Rohit Mathur; Haifeng Zhu; Frank K Braun; Rong-Hua Tao; Anita L Sabichi; Xue Ao; Hoyoung Maeng; Felipe Samaniego
Journal:  Blood       Date:  2013-04-18       Impact factor: 22.113

10.  Suramin induces and enhances apoptosis in a model of hyperoxia-induced oligodendrocyte injury.

Authors:  Simone Stark; Alexandra Schuller; Marco Sifringer; Bettina Gerstner; Felix Brehmer; Sven Weber; Rodica Altmann; Michael Obladen; Christoph Buhrer; Ursula Felderhoff-Mueser
Journal:  Neurotox Res       Date:  2008 May-Jun       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.